Loading
  • Cortisol Modulation
  • Stories
  • Careers
  • Contact
  • Home
  • About
    • Our Team
  • Products
    • Medical Information Request
  • Science
    • Pipeline and Clinical Trials
    • Cortisol Modulation
    • Therapeutic Areas
    • Publications
    • Investigator Initiated Studies
  • Resources
    • Grants
    • Compassionate use
    • State Required Notice
  • Investors
    • Overview
    • Press Releases
    • Events
    • Corporate Governance
    • Analyst Coverage
    • Stock Information
    • SEC Filings
  • Search
  • Menu Menu
  • Home
  • About
    • Teams
  • Products
    • Medical Information Request
  • Science
    • Pipeline and Clinical Trials
    • Cortisol Modulation
    • Therapeutic Areas
    • Publications
    • Investigator Initiated Studies
  • Resources
    • Grants
    • Compassionate use
    • State Required Notice
  • Stories
  • Careers
  • Contact
  • Investors
    • Overview
    • Press Releases
    • Events
    • Corporate Governance
    • Analyst Coverage
    • Stock Information
    • SEC Filings
  • Privacy Notice
  • Terms of Use
  • Site Map

DAZALS: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Of Dazucorilant, A Selective Glucocorticoid Receptor Modulator, In Amyotrophic Lateral Sclerosis

June 5, 2025

van den Berg et al. • 2025 • ENCALS 2025 Congress

Read more
https://corcept.com/wp-content/uploads/COR-logo.svg 0 0 jeremiah@devisedesigns.com https://corcept.com/wp-content/uploads/COR-logo.svg jeremiah@devisedesigns.com2025-06-05 01:30:352025-06-05 02:55:02DAZALS: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Of Dazucorilant, A Selective Glucocorticoid Receptor Modulator, In Amyotrophic Lateral Sclerosis

Safety, Pharmacokinetics, and Pharmacodynamics of the Selective Glucocorticoid Receptor Modulator Dazucorilant in Healthy Volunteers

October 6, 2023

Donaldson et al. • 2023 • NEALS 22nd Annual Meeting

Read more
https://corcept.com/wp-content/uploads/COR-logo.svg 0 0 jeremiah@devisedesigns.com https://corcept.com/wp-content/uploads/COR-logo.svg jeremiah@devisedesigns.com2023-10-06 00:00:002023-10-06 00:00:00Safety, Pharmacokinetics, and Pharmacodynamics of the Selective Glucocorticoid Receptor Modulator Dazucorilant in Healthy Volunteers

https://corcept.com/wp-content/uploads/2023/01/ENCALS2023-1.pdf

July 13, 2023

Donaldson et al. • 2023 • ENCALS Meeting 2023

Read more
https://corcept.com/wp-content/uploads/COR-logo.svg 0 0 jeremiah@devisedesigns.com https://corcept.com/wp-content/uploads/COR-logo.svg jeremiah@devisedesigns.com2023-07-13 00:00:002024-03-19 14:42:29Safety, Pharmacokinetics, and Pharmacodynamics of the Selective Glucocorticoid Receptor Modulator Dazucorilant in Healthy Volunteers

DAZALS: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Dazucorilant in Patients with Amyotrophic Lateral Sclerosis

February 3, 2023

Mann et al • 2022 • European Network to Cure ALS (ENCALS)

Read more
https://corcept.com/wp-content/uploads/COR-logo.svg 0 0 jeremiah@devisedesigns.com https://corcept.com/wp-content/uploads/COR-logo.svg jeremiah@devisedesigns.com2023-02-03 00:00:002024-03-14 21:30:28DAZALS: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Dazucorilant in Patients with Amyotrophic Lateral Sclerosis

Selection and early clinical evaluation of the brain-penetrant 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor UE2343 (Xanamem™).

November 15, 2017

Webster et al. • 2017 • Br J Pharmacol. 2017;174(5):396-408.

Read more
https://corcept.com/wp-content/uploads/COR-logo.svg 0 0 jeremiah@devisedesigns.com https://corcept.com/wp-content/uploads/COR-logo.svg jeremiah@devisedesigns.com2017-11-15 00:00:002024-03-14 21:45:03Selection and early clinical evaluation of the brain-penetrant 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor UE2343 (Xanamem™).

New selective glucocorticoid receptor modulators reverse amyloid-β peptide-induced hippocampus toxicity.

November 15, 2016

Pineau et al. • 2016 • Neurobiol Aging. 2016;45:109-122.

Read more
https://corcept.com/wp-content/uploads/COR-logo.svg 0 0 jeremiah@devisedesigns.com https://corcept.com/wp-content/uploads/COR-logo.svg jeremiah@devisedesigns.com2016-11-15 00:00:002024-03-14 21:45:45New selective glucocorticoid receptor modulators reverse amyloid-β peptide-induced hippocampus toxicity.

The selective glucocorticoid receptor modulator CORT108297 restores faulty hippocampal parameters in Wobbler and corticosterone-treated mice.

November 5, 2014

Meyer et al. • 2014 • J Steroid Biochem Mol Biol. 2014 Sep;143:40-8.

Read more
https://corcept.com/wp-content/uploads/COR-logo.svg 0 0 jeremiah@devisedesigns.com https://corcept.com/wp-content/uploads/COR-logo.svg jeremiah@devisedesigns.com2014-11-05 00:00:002024-03-14 21:54:57The selective glucocorticoid receptor modulator CORT108297 restores faulty hippocampal parameters in Wobbler and corticosterone-treated mice.

Age- and sex-dependent effects of early life stress on hippocampal neurogenesis.

May 15, 2014

Loi et al. • 2014 • Front Endocrinol (Lausanne). 2014;5:13.

Read more
https://corcept.com/wp-content/uploads/COR-logo.svg 0 0 jeremiah@devisedesigns.com https://corcept.com/wp-content/uploads/COR-logo.svg jeremiah@devisedesigns.com2014-05-15 00:00:002024-03-15 21:54:48Age- and sex-dependent effects of early life stress on hippocampal neurogenesis.

Mifepristone alters amyloid precursor protein processing to preclude amyloid beta and also reduces tau pathology.

November 15, 2013

Baglietto-Vargas et al. • 2013 • Biol Psychiatry. 2013;74(5):357-66.

Read more
https://corcept.com/wp-content/uploads/COR-logo.svg 0 0 jeremiah@devisedesigns.com https://corcept.com/wp-content/uploads/COR-logo.svg jeremiah@devisedesigns.com2013-11-15 00:00:002024-03-15 21:52:28Mifepristone alters amyloid precursor protein processing to preclude amyloid beta and also reduces tau pathology.

A single-day treatment with mifepristone is sufficient to normalize chronic glucocorticoid induced suppression of hippocampal cell proliferation.

August 15, 2012

Hu et al. • 2012 • PLoS One. 2012;7(9):e46224.

Read more
https://corcept.com/wp-content/uploads/COR-logo.svg 0 0 jeremiah@devisedesigns.com https://corcept.com/wp-content/uploads/COR-logo.svg jeremiah@devisedesigns.com2012-08-15 00:00:002024-03-15 21:53:56A single-day treatment with mifepristone is sufficient to normalize chronic glucocorticoid induced suppression of hippocampal cell proliferation.
Page 1 of 212

Categories

  • Endocrinology
  • Hypercortisolism (Cushing syndrome)
  • Metabolism
  • Neurology
  • Oncology
  • Other
  • Uncategorized

© 2024 Corcept Therapeutics, Incorporated

Privacy Notice | Terms of Use | Site Map | Your Privacy Choices | LinkedIn | Youtube

Privacy Notice

Terms of Use

Site Map

Your Privacy Choices

LinkedIn

Youtube

Scroll to top